Figure 2

Time- to-treatment failure and additional molecular alterations in ten patients withBRAF-mutant melanoma. Arrow indicates that the patient was still on study when the data was censored. A comprehensive list of alterations and their timing is found in Table 2 and Additional file 3. Red text refers to alterations seen in post-treatment biopsies.